I pay close attention to anything that can save me time. After reviewing my 2025 spending on generative AI, I made one big change.

The firm plans to back 15–20 IP-led companies over the next three to four years, focusing on hard science, frontier engineering and globally scalable technologies.

Among them was David Liu, a biochemist at the Broad Institute and Harvard University in Cambridge, Massachusetts. Liu isn’t a ...